Current Report Filing (8-k)
November 05 2018 - 11:53AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
November 5, 2018
Nexeon Medsystems Inc
(Exact name of registrant as specified in its
charter)
Nevada
|
|
000-55655
|
|
81-0756622
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
1910 Pacific Avenue,
Suite 20000
Dallas, Texas 75201
(Address of principal executive offices) (zip
code)
844-919-9990
|
(Registrant’s telephone number, including area code)
|
|
Not applicable
|
(Former name or former address, if changed since last report.)
|
Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by
check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 Regulation FD Disclosure.
Nexeon Medsystems
Inc (the “Company”) has made available an updated presentation about its business, a copy of which is filed as Exhibit
99.1 to this Current Report on Form 8-K (the “Report”) and is hereby incorporated by reference.
The information
contained in the presentation is summary information that should be considered in the context of the Company’s filings with
the Securities and Exchange Commission and other public announcements the Company may make by press release or otherwise from time
to time. The presentation speaks as of the date of this Report. While the Company may elect to update the presentation in the future
to reflect events and circumstances occurring or existing after the date of this Report, the Company specifically disclaims any
obligation to do so.
The presentation
contains forward-looking statements, and as a result, investors should not place undue reliance on these forward-looking statements.
The information
set forth in this Report, including without limitation the presentation, is not deemed “filed” for purposes of Section
18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing
under the Securities Act of 1933, as amended, or the Exchange Act, except as may be expressly set forth by specific reference in
such a filing.
Item 9.01 Financial Statements and
Exhibits.
(d) Exhibits.
The exhibits listed in the following
Exhibit Index are filed as part of this Current Report on Form 8-K.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
NEXEON MEDSYSTEMS INC
|
|
|
Dated: November
5, 2018
|
/s/
William Rosellini
|
|
William Rosellini
|
|
Chairman and Chief Executive Officer
|
Nexeon Medsystems (CE) (USOTC:NXNN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Nexeon Medsystems (CE) (USOTC:NXNN)
Historical Stock Chart
From Sep 2023 to Sep 2024